Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UGT2B7 | P16662 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27545157 | 0.84 | CYP2D6 (0.43) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL7214885 | 0.82 | CYP2D6 (0.44) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL4415603 | 0.82 | CYP2D6 (0.44) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL7217091 | 0.82 | CYP2D6 (0.44) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL10990788 | 0.82 | UGT2B7 (0.45) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL21821549 | 0.82 | MGAM (0.43) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL334982 | 0.80 | CYP2D6 (0.42) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL1245653 | 0.80 | CYP2D6 (0.56) | MGAMGAASIMGAM2CYP2D6 | |
| Hydrochloric Acid SCHEMBL334981 | 0.79 | CYP2D6 (0.41) | MGAMGAASIMGAM2CYP2D6 | |
| SCHEMBL7623909 | 0.79 | CYP2D6 (0.41) | MGAMGAASIMGAM2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-2852573-B1 | N-[3-(2-CARBOXYETHYL)PHENYL]-PIPERIDIN-1-YL ACETAMIDE DERIVATIVES AND THEIR USE AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma AG (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-9309198-B2 | N-[3-(2-carboxyethyl)phenyl]piperidin-1-ylacetamide derivatives and use thereof as activators of soluble guanylate cyclase | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-04 | — | — | US | disclosed |
| EP-2852573-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | disclosed |
| WO-2013174736-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152050-A1 | N-[3-(2-CARBOXYETHYL)PHENYL]PIPERIDIN-1-YLACETAMIDE DERIVATIVES AND USE THEREOF AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1A2, GUCY1A1, GUCY1B2 | MGAM 2435/4885GAA 1125/4885SI 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.